Literature DB >> 9441870

A common deletion mutation in European patients with Sjögren-Larsson syndrome.

W B Rizzo1, G Carney, V De Laurenzi.   

Abstract

Sjögren-Larsson syndrome (SLS) is an inherited neurocutaneous disorder characterized by ichthyosis, mental retardation, spasticity, and deficient activity of fatty aldehyde dehydrogenase (FALDH). We identified a frequent FALDH mutation in exon 9 among SLS probands of European descent. This mutation is a 2-bp deletion of nucleotides GA 1297-1298 and results in premature termination of translation at codon 435 along with substitution of Arg and Cys for Glu433 and Gly434 respectively. The GA del1297-8 mutation was found in 10 of 21 European SLS probands and could be readily detected using an allele-specific PCR method. This GA deletion mutation or a previously identified common point mutation 9C943Y) was present in 66% of the European SLS probands, and the two mutations together accounted for 48% of the SLS alleles. Screening European patients for these two common mutations should be useful for DNA-based diagnosis of SLS and genetic counseling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9441870     DOI: 10.1006/bmme.1997.2640

Source DB:  PubMed          Journal:  Biochem Mol Med        ISSN: 1077-3150


  7 in total

1.  Molecular basis of Sjögren-Larsson syndrome: frequency of the 1297-1298 del GA and 943C-->T mutation in 29 patients.

Authors:  L Ijlst; W Oostheim; M van Werkhoven; M A Willemsen; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  The molecular basis of Sjögren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene.

Authors:  W B Rizzo; G Carney; Z Lin
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 3.  Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency.

Authors:  William B Rizzo
Journal:  Mol Genet Metab       Date:  2006-09-22       Impact factor: 4.797

4.  Phenotypic and mutational spectrum of thirty-five patients with Sjögren-Larsson syndrome: identification of eleven novel ALDH3A2 mutations and founder effects.

Authors:  Mohamed S Abdel-Hamid; Mahmoud Y Issa; Hasnaa M Elbendary; Sherif F Abdel-Ghafar; Karima Rafaat; Heba Hosny; Marian Girgis; Ghada M H Abdel-Salam; Maha S Zaki
Journal:  J Hum Genet       Date:  2019-07-05       Impact factor: 3.172

5.  Novel mutation in Sjogren-Larsson syndrome is associated with divergent neurologic phenotypes.

Authors:  Kathleen Davis; Kenton R Holden; Dana S'Aulis; Claudia Amador; M Gisele Matheus; William B Rizzo
Journal:  J Child Neurol       Date:  2012-10-03       Impact factor: 1.987

6.  Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.

Authors:  William B Rizzo
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-10       Impact factor: 0.694

Review 7.  Sjogren-Larsson Syndrome: Mechanisms and Management.

Authors:  Parayil Sankaran Bindu
Journal:  Appl Clin Genet       Date:  2020-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.